NCT05101486View on ClinicalTrials.gov

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

755

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

March 28, 2022

Study Completion Date

September 20, 2022

Conditions
Respiratory Syncytial Virus Prevention
Interventions
BIOLOGICAL

Ad26.RSV.PreF-based Vaccine

Ad26.RSV.PreF-based Vaccine will be administered as single IM injection.

Trial Locations (13)

21075

Centennial Medical Group, Elkridge

28277

American Health Network, LLC, Charlotte

30331

Atlanta Center for Medical Research, Atlanta

32720

Accel Research Sites, DeLand

33126

Pharmax Research Clinic Inc, Miami

33135

Suncoast Research Group, Miami

33173

Suncoast Research Associates, LLC, Miami

35216

Achieve Clinical Research, LLC, Vestavia Hills

35611

North Alabama Research Center, LLC, Athens

45212

CTI Clinical Trial and Consulting Services, Cincinnati

68516

Be Well Clinical Studies, Lincoln

85023

Hope Research Institute, Phoenix

06460

Clinical Research Consulting, Milford

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT05101486 - A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years | Biotech Hunter | Biotech Hunter